Celcuity (CELC) Non-Current Assets (2016 - 2025)
Celcuity (CELC) reported Non-Current Assets of $899000.0 for Q4 2025, up 62.86% on a YoY basis from $552000.0 in Q4 2024, and up 77.32% quarter-over-quarter from $507000.0 in Q3 2025.
Celcuity (CELC) Non-Current Assets (2016 - 2025) Analysis & Trends
Celcuity has reported Non-Current Assets for 10 years, with the latest figure at $899000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 62.86% year-over-year to $899000.0; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (changed 0.08% YoY), and the FY2025 full-year result was $899000.0, up 62.86% from the prior year.
- Non-Current Assets for Q4 2025 stood at $899000.0, up from $507000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $899000.0 in Q4 2025, with the low at $387356.0 in Q2 2022.
- Historically, Non-Current Assets has averaged $601580.8 across 5 years, with a median of $598035.5 in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Assets slumped 32.56% — and 2023, when it surged 83.51%.
- Celcuity's Non-Current Assets stood at $554345.0 in 2021, then declined by 8.62% to $506560.0 in 2022, then rose by 24.13% to $628801.0 in 2023, then decreased by 12.21% to $552000.0 in 2024, then jumped by 62.86% to $899000.0 in 2025.
- The last three Non-Current Assets figures came in at $899000.0 (Q4 2025), $507000.0 (Q3 2025), and $488000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 39.71 Mn |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 899,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 899,000.00 |
| Sep 30, 2025 | 507,000.00 |
| Jun 30, 2025 | 488,000.00 |
| Mar 31, 2025 | 530,000.00 |
| Dec 31, 2024 | 552,000.00 |
| Sep 30, 2024 | 598,531.00 |
| Jun 30, 2024 | 613,623.00 |
| Mar 31, 2024 | 657,935.00 |
| Dec 31, 2023 | 628,801.00 |
| Sep 30, 2023 | 672,746.00 |
| Jun 30, 2023 | 710,851.00 |
| Mar 31, 2023 | 775,276.00 |
| Dec 31, 2022 | 506,560.00 |
| Sep 30, 2022 | 597,540.00 |
| Jun 30, 2022 | 387,356.00 |
| Mar 31, 2022 | 486,001.00 |
| Dec 31, 2021 | 554,345.00 |
| Sep 30, 2021 | 655,119.00 |
| Jun 30, 2021 | 557,846.00 |
| Mar 31, 2021 | 653,086.00 |